291 related articles for article (PubMed ID: 36715750)
1. mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development.
Chaki S; Watanabe M
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1451-1462. PubMed ID: 36715750
[TBL] [Abstract][Full Text] [Related]
2. mGlu2/3 receptor as a novel target for rapid acting antidepressants.
Chaki S
Adv Pharmacol; 2020; 89():289-309. PubMed ID: 32616210
[TBL] [Abstract][Full Text] [Related]
3. Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine.
Chaki S; Fukumoto K
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871246
[TBL] [Abstract][Full Text] [Related]
4. mGlu2/3 receptor antagonists.
Chaki S
Adv Pharmacol; 2019; 86():97-120. PubMed ID: 31378257
[TBL] [Abstract][Full Text] [Related]
5. mGlu2/3 Receptor Antagonists as Novel Antidepressants.
Chaki S
Trends Pharmacol Sci; 2017 Jun; 38(6):569-580. PubMed ID: 28413097
[TBL] [Abstract][Full Text] [Related]
6. Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions.
Onisiforou A; Georgiou P; Zanos P
Pharmacol Biochem Behav; 2023 Feb; 223():173531. PubMed ID: 36841543
[TBL] [Abstract][Full Text] [Related]
7. (
Zanos P; Highland JN; Stewart BW; Georgiou P; Jenne CE; Lovett J; Morris PJ; Thomas CJ; Moaddel R; Zarate CA; Gould TD
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6441-6450. PubMed ID: 30867285
[TBL] [Abstract][Full Text] [Related]
8. Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.
Dogra S; Conn PJ
Neuropharmacology; 2021 Sep; 196():108687. PubMed ID: 34175327
[TBL] [Abstract][Full Text] [Related]
9. [The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant].
Chaki S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Aug; 32(4):219-26. PubMed ID: 23012890
[TBL] [Abstract][Full Text] [Related]
10. The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice.
Pałucha-Poniewiera A; Podkowa K; Rafało-Ulińska A
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110239. PubMed ID: 33400944
[TBL] [Abstract][Full Text] [Related]
11. The role of mGlu
Pałucha-Poniewiera A
Pharmacol Biochem Behav; 2022 Oct; 220():173454. PubMed ID: 36038006
[TBL] [Abstract][Full Text] [Related]
12. Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery.
Musazzi L
Expert Opin Drug Discov; 2021 Feb; 16(2):147-157. PubMed ID: 32962432
[TBL] [Abstract][Full Text] [Related]
13. mGlu2/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects.
Witkin JM
Pharmacol Biochem Behav; 2020 Mar; 190():172854. PubMed ID: 31954773
[TBL] [Abstract][Full Text] [Related]
14. Targeting of Metabotropic Glutamate Receptors for the Development of Novel Antidepressants.
Chaki S; Koike H; Fukumoto K
Chronic Stress (Thousand Oaks); 2019; 3():2470547019837712. PubMed ID: 32500107
[TBL] [Abstract][Full Text] [Related]
15. mGlu receptors as potential targets for novel antidepressants.
Chaki S; Fukumoto K
Curr Opin Pharmacol; 2018 Feb; 38():24-30. PubMed ID: 29486373
[TBL] [Abstract][Full Text] [Related]
16. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants.
Chaki S; Ago Y; Palucha-Paniewiera A; Matrisciano F; Pilc A
Neuropharmacology; 2013 Mar; 66():40-52. PubMed ID: 22640631
[TBL] [Abstract][Full Text] [Related]
17. The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits.
Witkin JM; Monn JA; Schoepp DD; Li X; Overshiner C; Mitchell SN; Carter G; Johnson B; Rasmussen K; Rorick-Kehn LM
J Pharmacol Exp Ther; 2016 Jul; 358(1):71-82. PubMed ID: 27189960
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
[TBL] [Abstract][Full Text] [Related]
19. mGlu
Joffe ME; Santiago CI; Oliver KH; Maksymetz J; Harris NA; Engers JL; Lindsley CW; Winder DG; Conn PJ
Neuron; 2020 Jan; 105(1):46-59.e3. PubMed ID: 31735403
[TBL] [Abstract][Full Text] [Related]
20. Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.
Chruścicka-Smaga B; Machaczka A; Szewczyk B; Pilc A
Pharmacol Rep; 2023 Dec; 75(6):1341-1349. PubMed ID: 37932583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]